Novartis makes an open offer to increase stake in Novartis India Ltd.
- Details
- Category: Novartis
Novartis has announced a tender offer to acquire an additional stake of up to approximately 39% in its majority-owned Indian subsidiary, Novartis India Ltd., from public shareholders at a price of Rs 351 per share.
HemCon Medical Technologies, Inc. Announces Improved Results from Live Nail Infection Study
- Details
- Category: Clinical Trials
HemCon has announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon's continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology.
EMERFLU®, pandemic influenza vaccine for humans, approved in Australia
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that its pandemic influenza vaccine for human use Emerflu®, has been granted marketing authorization from the Australian Therapeutic Goods Administration (TGA). Emerflu® vaccine is now approved for the prevention of pandemic
influenza in Australia upon official declaration of a pandemic.
Glivec® recommended for use in Europe as first post-surgery treatment for GIST
- Details
- Category: Novartis
Novartis has received a positive opinion supporting European Union (EU) approval of Glivec® (imatinib)* as a post-surgery treatment for patients at significant risk of relapse following removal of gastrointestinal stromal tumors (GIST). The Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Glivec based on positive findings from a pivotal Phase III study, which showed that use of Glivec after surgery reduces risk of recurrence by approximately 89%[1].
New image of therapy for erectile difficulties
- Details
- Category: Bayer
At the European Association of Urology (EAU) congress in Stockholm, Sweden, Bayer Schering Pharma presented new data that might change the image of therapy for erectile difficulties. Two independent placebo-controlled clinical studies demonstrated that Levitra® (vardenafil HCI) results in a significantly prolonged erection(1,2) which is a prerequisite for an increase in the duration of intercourse.
Merck KGaA and Fast Forward, LLC Announce Collaboration
- Details
- Category: Merck Group
Merck KGaA announced that its Merck Serono division and Fast Forward, LLC, a wholly-owned subsidiary of the American National Multiple Sclerosis Society, have entered a collaborative partnership to evaluate and fund promising multiple sclerosis (MS) research projects. Proposals will be jointly developed by Merck Serono and Fast Forward. Merck will provide up to $19 million in funding.
U.S. Patent & Trademark Office Grants Reissue Patent Relating to Lipitor
- Details
- Category: Pfizer
Pfizer Inc announced that the U.S. Patent & Trademark Office has granted reissue patent RE40667, relating to Lipitor. The company had applied for the reissue patent in January 2007, in order to correct a technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.
More Pharma News ...
- Roche acquires innovatis AG to complement its product portfolio
- The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
- Sanofi-aventis invests â¬100 million in new facility in Mexico
- Roche Annual General Meeting: dividend raised by 9 percent
- Merck and Schering-Plough to Merge
- Roche increases offer price for Genentech shares to US$ 93 per share
- Lundbeck meets all of its financial forecasts for 2008 and expects continuing growth in 2009